Kv1.5-blocker for the selective increase of atrial contractility and treatment of cardiac insufficiency

Details for Australian Patent Application No. 2005218731 (hide)

Owner Sanofi-Aventis Deutschland GmbH

Inventors Wirth, Klaus

Agent Watermark

Pub. Number AU-A-2005218731

PCT Pub. Number WO2005/084675

Priority 10 2004 009 931.6 26.02.04 DE

Filing date 12 February 2005

Wipo publication date 15 September 2005

International Classifications

A61K 31/166 (2006.01) - having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/4406 (2006.01) - only substituted in position 3, e.g. zimeldine

Event Publications

14 September 2006 PCT application entered the National Phase

  PCT publication WO2005/084675 Priority application(s): WO2005/084675

9 September 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005218733-Laser-weldable which are transparently, translucently or opaquely dyed by means of colorants

2005218729-New therapeutic use for a group of sulphated polysaccharides